20
Aurobindo Pharma Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is CARMUSTINE USP, with a corresponding US DMF Number 32343.
Remarkably, this DMF maintains an Active status since its submission on December 26, 2017, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 25, 2018, and payment made on December 22, 2017, indicating their dedication to facilitating drug approvals, Categorized as Type II